The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy - PubMed
4 hours ago
- #HER2
- #Immunotherapy
- #Breast Cancer
- HER2-positive breast cancer shows higher RANK expression compared to HER2-negative tumors.
- Triple-targeting therapy (Denosumab, Pertuzumab, Trastuzumab) improves disease-free survival in RANK+/HER2+ patients.
- In mouse models, the triple-targeting combination significantly reduces tumor volume and weight.
- STAT3 expression is elevated in HER2-negative tissues, while mTOR is higher in HER2-negative compared to HER2+ samples.
- Adding immune checkpoint inhibitors (Nivolumab, Ipilimumab) to triple-targeting therapy further reduces cell viability in HER2+ breast cancer cells.
- The RANK-RANKL axis plays a key role in tumor growth and immune regulation.